



HAL
open science

The circadian clock and liver function in health and disease

Atish Mukherji, Shannon M. Bailey, Bart Staels, Thomas F. Baumert

► **To cite this version:**

Atish Mukherji, Shannon M. Bailey, Bart Staels, Thomas F. Baumert. The circadian clock and liver function in health and disease. *Journal of Hepatology*, 2019, 71 (1), pp.200-211. 10.1016/j.jhep.2019.03.020 . hal-02390252

HAL Id: hal-02390252

<https://hal.science/hal-02390252v1>

Submitted on 2 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The Circadian Clock and Liver Function in Health and Disease

Atish Mukherji¹, Shannon M. Bailey³, Bart Staels⁴, and Thomas F. Baumert^{1,2}

¹Institut de Recherche sur les Maladies Virales et Hépatiques INSERM, UMR 1110, Université de Strasbourg Strasbourg, France,

²Pôle Hépato-Digestif, Institut Hospitalo-Universitaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France,

³Department of Pathology, School of Medicine, University of Alabama at Birmingham, USA,

⁴Université de Lille-European Genomic Institute for Diabetes, Institut Pasteur de Lille, CHU de Lille, INSERM UMR 1011, Lille, France.

Corresponding Authors: Prof. Thomas F. Baumert, M.D and, Dr. Atish Mukherji, Ph.D,

Institut de Recherche sur les Maladies Virales et Hépatiques, Inserm U1110, 3 Rue Koeberlé, 67000 Strasbourg, France. Tel: +33 3 68 85 37 03; fax: +33 3 68 85 37 24.

e-mails thomas.baumert@unistra.fr and mukherji@unistra.fr

Conflict of interest: The authors disclose no conflicts of interest.

Word Counts: abstract: 217; main text: 4956.

Abstract:

All organisms are subjected each day to changes in the light intensity generated by the Earth's rotation around its own axis. To anticipate this geo-physical variability, and to appropriately respond biochemically, most species, including mammals, have evolved an approximate 24-hour endogenous timing mechanism known as the circadian clock (CC). The 'clock' is self-sustained, cell autonomous and present in every cell type. At the core of the clock resides the CC-oscillator, an exquisitely crafted transcriptional-translational feedback system. Remarkably, components of the CC-oscillator not only maintain daily rhythmicity of their own synthesis, but also generate temporal variability in the expression levels of numerous target genes through transcriptional, post-transcriptional and post-translational mechanisms, thus, ensuring proper chronological coordination in the functioning of cells, tissues and organs, including the liver. Indeed, a variety of physiologically critical hepatic functions and cellular processes are CC-controlled. It is not surprising then, that the modern lifestyle (e.g. travel and jet lag, night and rotating shift work), which force 'circadian misalignment' have emerged as major contributors to global health problems including obesity, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Here, we provide an overview of the CC-dependent pathways which play critical roles in mediating several hepatic functions under physiological conditions and, whose deregulations are implicated in chronic liver disease including NASH and alcoholic liver disease (ALD).

Introduction

The word circadian is Latin in origin, and translates to 'about a day', hence, oscillations of ~24 hours are referred as circadian rhythms. These rhythms are generated by the Earth's 24 hours rotation, which, in turn drives the light-dark cycle. This daily change in the light intensity leads to overt rest-activity and feeding-fasting cycles, e.g. human beings are diurnal and conduct most of their activities during the day and rest at night. Teleologically, these rhythms have allowed organisms to anticipate changes in the external environment (e.g. the light-dark cycle), and to respond by adjusting CC-driven physiological functions, e.g. metabolism⁽¹⁻⁷⁾. Accordingly, the CC-controlled behavioral synchronization with feeding-fasting cycles generates diurnal variations in metabolic activities, which, in turn, ensures energy homeostasis. Recent investigations have established that, in mammals, the expression of numerous genes in different organs (including the liver) display circadian rhythmicity, which enables regulation of both anabolism and catabolism⁽¹⁻⁶⁾. Indeed, hepatocyte activities such as nutrient uptake, processing, assimilation and detoxification exhibit remarkable diurnal variations, which enable their alignment with food availability and energetic demand. Physiologically these 'metabolic rhythms' are generated and maintained by the dynamic interactions between the CC and timing cues e.g. light and food (time of eating and its quality). However, our modern lifestyle (jet lag, shift-work, energy-dense foods etc.), which often 'misaligns' CC functioning has recently emerged as prominent contributors to different metabolic diseases and carcinogenesis⁽⁸⁻¹³⁾.

Here, we focus on how the CC regulates hepatic metabolism to maintain homeostasis and, also provide an overview of how deregulation of CC-controlled pathways could lead to the development of non-alcoholic fatty liver (NAFL) and its progression to NASH. Furthermore, we also discuss evidences linking the CC and alcohol-induced liver disease (ALD).

The anatomic and molecular organization of the mammalian CC-system

Retinal photoreceptors (rods and cones) transform photic energy to electrical impulses and convey them to the brain through retinal ganglion cells (RGC). A subset of RGCs expressing the photopigment melanopsin are intrinsically sensitive to the visible spectrum and directly relay the photic signal to a hypothalamic region called the suprachiasmatic nucleus (SCN)⁽⁷⁻⁸⁾. Hence, anatomically, the mammalian circadian system is hierarchical, whereby the light-entrained SCN is the 'central' CC. In turn, the SCN-CC by utilizing humoral and neuronal mechanisms communicates the 'time cue' (a. k. a; 'Zeitgeber'; ZT) to other organs, thereby enabling the synchronization of peripheral CCs (PCCs)⁽¹⁻⁸⁾.

At the molecular level, the components of the central SCN and PCCs are the same and are identically organized in multiple transcriptional-translational feedback systems (Figure 1) and generate a cell autonomous self-sustained CC-oscillator with a periodicity of ~24 hours⁽¹⁻⁶⁾. The heart of this oscillator is constituted by a heterodimer of transcription factors (TFs), the Brain and Muscle ARNTL-Like protein1 (BMAL1) associated with the Circadian Locomotor Output Cycles Kaput (CLOCK), which activate genes containing E-Box DNA Binding Sequences (DBS) in their promoter-enhancer regions, including those of *Period* (*Per1*, *Per2*) and *Cryptochrome* (*Cry1*, *Cry2*) genes. In turn, PER1/2 and CRY1/2 proteins heterodimerize to inhibit the transcriptional activity of the BMAL1/CLOCK-complex (the first-loop of the oscillator), thereby eventually suppressing their own expression (Figure 1). BMAL1/CLOCK-also binds to the E-Box DBSs present in the genes of the nuclear receptors *Rev-Erba* and *Rev-Erbβ* to activate their transcription, while the presence of RORE DBSs in the *Rev-Erba/β* genes mediate their autorepression. REV-ERBs also inhibit (through RORE DBSs) the transcription of their activators *Bmal1* and *Clock*, thus constituting the second-loop of the CC-oscillator. At the beginning of the active phase, levels of REV-ERBs (which are repressors of transcription) decrease, while simultaneously protein levels of transcriptional activators RORα/γ increase, which then bind to RORE DBSs present in *Bmal1* and *Clock* and activate their transcription, thereby initiating the next round of CC oscillation. Additionally, BMAL1/CLOCK-induces expression of the transactivator D-Box binding protein (*Dbp*). The DBP activator and the E4BP4 repressor (which is activated by RORα/γ and repressed by REV-ERBα) competes for binding to D-Box DBSs present in several CC-controlled genes (CCGs). These inter-connected feed-back loops generate circadian oscillations of the expression of ~20% of the genome, such that CCGs containing RORE DBS are transcribed during the active phase, while E-Box and D-Box DBS-bearing genes are expressed during the rest phase^(1-6,14). Moreover, post-translational modifications of CC-components also aids in further fine-tuning of the CC-oscillator functioning. Thus, utilizing multiple mechanisms the CC-oscillator drives a temporally-restricted gene expression pattern, which lies at the core of generating distinct biochemical outputs in individual organs.

Feeding cycles and peripheral clocks

Establishment of feeding cycles as the prominent *zeitgeber* for peripheral tissues, including the liver⁽¹⁵⁻¹⁶⁾, has revealed the existence of extensive cross-talk between metabolism and the CC, and the list of mechanisms through which metabolic signals influence CC functioning and, *vice versa*, are increasing rapidly⁽¹⁻⁵⁾. The dominance of feeding cycles on the liver-clock was

demonstrated in ‘arrhythmic’ *Cry1/2* mutant mice, in which an imposed feeding regime recovered ‘rhythmicity’ in circadian gene expression pattern ⁽¹⁷⁾. Furthermore, changing the feeding time from active to rest phases in mice shifts the PCCs by ~12 hours ⁽¹⁵⁻¹⁶⁾, driven by metabolic alterations acting through PPAR α and CREB ⁽¹⁸⁾. Notably, high-fat diet (HFD)-induced ‘reprogramming’ of the hepatic CC ⁽¹⁹⁾ can be prevented by restricting HFD feeding during the active phase ⁽²⁰⁾. One physiological example of CC-metabolism crosstalk is provided by BMAL1/CLOCK-dependent transcription of the nicotinamide phosphoribosyl transferase (*NAMPT*) gene, which is involved in NAD⁺ synthesis ⁽²¹⁻²²⁾. CC-dictated NAMPT expression ensures not only a rhythmicity in NAD⁺ synthesis but also regulates the activities of NAD⁺-dependent proteins ⁽¹⁻⁵⁾, e.g. the SIRT1 deacetylase and the ADP-ribosyltransferase PARP-1. In turn, SIRT1 determines: (i) the activity of BMAL1/CLOCK-complex towards their target genes and, (ii) the stability of PER2 protein, which together maintain CC-oscillator functioning ⁽¹⁻⁵⁾. Akin to NAD⁺, feedback regulation between the CC and heme biosynthesis has also been demonstrated ⁽²³⁻²⁴⁾. Thus, by controlling metabolite sensors (NAD⁺, heme etc.), the CC gauges the cellular energetic and redox status to reset the oscillator with metabolism. Altogether, these investigations have established metabolism as a critical modulator of PCCs.

Circadian regulation of hepatic functions

Given the centrality of the liver in maintaining whole-body physiology, several high-throughput circadian time-course studies have been performed in mouse models investigating cistrome ⁽²⁵⁻²⁸⁾, transcriptome ⁽²⁹⁻³⁰⁾, proteome ⁽³¹⁻³³⁾, and lipidome ⁽³⁴⁻³⁵⁾. Circadian transcriptome analyses have revealed two broad crests of transcription in liver, corresponding to the transition between successive active and rest phases ⁽¹⁻⁵⁾. Cistromic analyses ⁽²⁵⁻²⁸⁾ revealed that these two distinct mRNA repertoires are generated due to the rhythmicity of the CC-oscillator, which enables periodic recruitment/removal of TFs and coregulators to epigenetically alter the chromatin landscape of CCGs. Cellular processes like DNA repair, ribosome biogenesis, autophagy, ER-stress are also subjected to circadian regulation, but mainly at the post-translational level ⁽³¹⁻³³⁾. Altogether, these investigations have revealed an unprecedented level of CC-control on hepatic physiology (Figure 2). Importantly, deregulation of these CC-regulated pathways/processes has been shown to contribute to the development of NAFLD and other diseases.

The circadian clock and pathophysiology of NAFLD and NASH

Over the last decades, life-style changes have shifted health care priorities world-wide from infectious to metabolic diseases⁽³⁶⁻³⁸⁾. In the context of liver disease, vaccination can now prevent hepatitis B virus (HBV) infection and antivirals can control chronic HBV infection^(39-40,43), and recently developed direct-acting antivirals can cure chronic hepatitis C virus in a large majority of infected patients⁽⁴¹⁻⁴³⁾. In contrast, the prevalence of metabolic liver diseases such as NAFL and NASH are increasing dramatically in conjunction with obesity and type II diabetes^(36-38,44). NAFLD, is a continuous spectrum of disease initiated by excessive triglyceride (TG) accumulation in the liver. In the absence of concomitant inflammation and hepatocytic injury, this state is largely benign and commonly referred as nonalcoholic fatty liver (NAFL) or simple steatosis^(36-38, 45). However, chronic NAFL usually drives simple steatosis to steatohepatitis (NASH), which is typified by concomitant presence of both lobular inflammation and hepatocellular damage (ballooning). Moreover, NASH predisposes to fibrosis, progressing to cirrhosis and hepatocellular carcinoma (HCC)⁽³⁶⁻³⁸⁾. Like every other aspect of the metabolic syndrome, development of NAFLD and NASH is highly complex which has been reviewed extensively elsewhere^(36-38,46-48). Almost two decades earlier the 'two-hit' theory⁽⁴⁹⁾ was posited to explain NASH pathogenesis. This theory proclaimed that unrestrained TG deposition in the liver (first-hit; NAFL) leads to 'secondary hits' such as oxidative stress, which ultimately leads to NASH. However, with increasing knowledge of metabolism and associated pathologies, NAFLD is now considered as a multi-factorial systemic metabolic disorder⁽³⁶⁻³⁸⁾. Indeed, investigations have revealed crucial roles for intestine, adipose tissue and muscle in NAFLD development. Importantly, insulin resistance also plays a critical, if not indispensable role in NAFLD^(36,38,45).

Systemic energy homeostasis is maintained by communications between numerous intra- and inter-organ signaling networks and at the core of NAFLD pathogenesis lies the inability of the liver to effectively metabolize carbohydrates and fatty acids^(36-38, 50). The pathology of NAFLD is generally initiated by perturbations in free fatty acid (FFA) metabolism, which drives excessive TG accumulation in hepatocytes⁽³⁶⁻³⁷⁾. Increased FFA release from adipocytes due to insulin resistance⁽⁵¹⁾ and conversion of excess carbohydrates to FFA via hepatic *de novo* lipogenesis (DNL)⁽⁵²⁾ are two major sources of TG deposition during NAFLD development, in addition to excess caloric intake. In hepatocytes, FFA can either undergo β -oxidation or be re-esterified as TG. In turn, this pool of TG can either be exported as VLDL particles or stored in lipid droplets⁽³⁶⁻³⁸⁾. The capacity to metabolize FFA through either β -oxidation or TG formation when overwhelmed (perturbation of dynamic lipid fluxes), leads to the accumulation of lipotoxic species. This buildup

of lipotoxic molecules in turn damages hepatocytes through several pathways; e.g. enhanced ER- and oxidative- stress, a dysfunctional unfolded protein response (UPR), and inflammasome activation to finally lead to NAFLD development ^(37,50,53-54). In the subsequent sections we describe some of these hepatic functions and processes which show diurnal variations and whose deregulation could predispose towards NAFLD/NASH (Figure 3).

Circadian control of glucose metabolism

The liver is the principal gluconeogenic organ in mammals, and participates, along with several other organs, to maintain homeostatic blood glucose levels. The CC sustains the physiological levels of blood glucose by synchronizing tissue-specific mechanisms of glucose metabolism. Accordingly, the SCN-clock controls the feeding/fasting rhythms, while PCCs (liver, pancreatic β -cells, skeletal muscles) drive temporally coordinated gene expression programs to maintain physiological levels of glucose in blood ⁽⁵⁵⁾.

One of the first studies indicating a role for the liver-CC-oscillator in glucose metabolism showed that *Bmal1* ablation in hepatocytes reduced expression of the glucose transporter (*Glut2*), leading to a decreased post-absorptive glucose uptake in mutant mice ⁽⁵⁶⁾. Post-hepatocytic entry, glucose is phosphorylated to glucose-6-phosphate (G6P), which can be either used (through glycolysis or hexose monophosphate pathway) or stored (glycogen synthesis). Remarkably, the CC influences all these processes ^(2,6). For example, the hepatic expression of glucokinase (*Gck*), which controls both glycolysis and glycogen synthesis is rhythmic reaching its zenith during the transition from the rest-phase to the active-phase ^(17,57) and temporally matches the surge of post-prandial insulin secretion from the pancreas. This increase in insulin secretion also leads to a pulsatile glycogen synthase kinase 3 (GSK3) activity in liver ⁽¹⁷⁾, which, in turn, determines: (i) the enzymatic activity of glycogen synthase, (ii) the activity of the glycosylating enzyme O-linked N-acetylglucosamine transferase (OGT), thereby, generating rhythmicity in the glycosylation levels of numerous proteins ⁽⁵⁸⁾ and, (iii) the stability of REV-ERB α ^(2,4), which in turn dictates the expression of many CCGs. By controlling the expression of trans-activators *Klf10* ⁽⁵⁹⁾ and *Hnf4a* ⁽⁶⁰⁾, the liver-CC further dictates transcription of several genes, which are involved in glucose metabolism.

The CC also controls glucagon-induced gluconeogenesis in liver by regulating the duration of hepatic cAMP production ⁽⁶¹⁾. It was demonstrated that the interaction of the CC-component CRY1 with the regulatory α -subunit of the glucagon receptor blocks hepatic cAMP accumulation during the circadian active phase, thus leading to a temporally-restricted (between rest- and active-

phases) activation of the gluconeogenic transcription factor CREB ^(55,61). Moreover, BMAL1-regulates the expression of the *Pgc1 α* gene ⁽⁶²⁾, which is a coactivator of the gluconeogenic transcription program ⁽²⁻⁴⁾. Thus, by employing multiple strategies the CC controls diverse mechanisms which co-operate to maintain physiological glucose levels ^(1-5, 55).

Circadian regulation of liver lipid metabolism

In a seminal study, Turek et al. ⁽⁶³⁾ demonstrated that *Clock* mutant mice are obese and have increased blood levels of cholesterol and TG. Since then, multiple genetic studies in mice models have established the CC as a critical regulator of lipid metabolism ⁽⁶⁴⁻⁶⁶⁾. Indeed, plasma levels of FFA, TG and cholesterol display diurnal variations, and are altered upon mutations of CC-components. Notably, the liver plays a crucial role in generating these variations in blood levels. Indeed, hepatocyte-specific ablation of *Rev-Erba*/ β was found to increase plasma levels of FFA, TG and cholesterol ^(27,66). In this regard, a lipidomic study revealed that TG, phosphatidyl inositol and phosphatidyl choline preferentially accumulate in mouse liver during the rest phase ⁽³⁵⁾. Mechanistically, the CC controls enzymes that are critically involved in regulating various steps of lipid metabolism. As example, expression of the enzyme ATP citrate lyase, which drives mitochondrial export of acetyl Coenzyme A (acetyl CoA), is maximal at the beginning of the active phase ⁽¹⁷⁾. Cytosolic acetyl CoA is carboxylated by acetyl CoA carboxylase (ACC1) to generate malonyl CoA an essential step in fatty acid synthesis. It is well known that AMPK inactivates ACC by phosphorylation ⁽²⁻⁴⁾, and CCs by controlling AMPK 'temporally gate' ACC activity ⁽⁶⁷⁾. Furthermore, the liver CC by controlling the transcription of *Elovl3*, *Elovl6*, *Fas* etc. 'times' fatty acid synthesis ⁽²⁻⁶⁾. Moreover, the expression of enzymes regulating β -oxidation (*Cpt1/2*) and ketone-body production (*Hmgcs2*) ⁽⁶⁸⁻⁶⁹⁾, as well as their transcriptional regulators PPAR α and δ are also circadian in nature ⁽⁶⁰⁾.

Hepatic TG synthesis from glycerol-3-phosphate is a multistep process and expression of several genes (*Gpat2*, *Agpat1/2*, *Lipin1/2* and *Dgat2*) that regulate successive steps of TG synthesis is circadian in nature ⁽³⁵⁾. Importantly, by controlling the transcription of *Pnpla3* the CC also regulates lipid droplet dynamics ⁽³⁵⁾. Altogether, in *ad libitum* fed mice livers, a prominent crest and trough of TG levels are observed during the rest (~ZT8) and active phases (~ZT20). Additionally, REV-ERB α -controlled expression of *Insig2* regulates the activity of SREBP1c, thereby leading to CC-command over lipogenesis ⁽⁷⁰⁾.

Clock and metabolism of bile acids

Intestinal absorption of lipids requires bile acids (BA), which are synthesized in hepatocytes. Besides lipid absorption, recent evidences have established BA as signaling molecules ⁽⁷¹⁻⁷²⁾. BA are physiological ligands for FXR and the G-protein coupled receptor TGR5 and can activate signaling modules such as the MAPK-pathway ⁽⁷¹⁻⁷²⁾. By regulating these diverse signaling networks, BA not only control their own levels but also those of TG, cholesterol and glucose homeostasis ⁽⁷¹⁻⁷²⁾. BA synthesis is controlled by a transcriptional feed-back loop consisting of the nuclear receptors FXR and SHP and hormone FGF15 (FGF19 in humans) ^(38,73). Hepatic expressions of both FXR and SHP ⁽⁶⁰⁾ and the intestinal secretion of FGF15 are 'clock'-gated ⁽⁷⁴⁾, which, together, drive the circadian transcription of cholesterol 7 α -hydroxylase (*Cyp7a1*), the rate-limiting enzyme in the classical BA synthesis pathway. Moreover, the CC-output regulator DBP controls *Cyp7a1* transcription to restrict its temporal expression ⁽⁷⁵⁾. Additionally, by regulating the transcription of both E4BP4 and SHP, REV-ERB α directly regulates the expression of *Cyp7a1*. ⁽⁷⁶⁾ Altogether, these mechanisms cooperatively generate diurnal rhythmicity in BA levels (Figure 3), which is also observed in humans ⁽⁷⁷⁾.

Clock-controlled cellular processes and NAFLD

Along with controlling systemic metabolism ⁽²⁻⁵⁾, several investigations have indicated a critical role for the CC-machinery in regulating autophagy, ER stress and oxidative stress ⁽⁷⁸⁻⁸⁰⁾, all of which may participate in NAFLD and in its transition to NASH ⁽³⁶⁻³⁷⁾. For example, in murine livers, expression of key genes controlling different steps of the autophagic process display circadian rhythms, thereby leading to an overall diurnal rhythm in autophagic activity ⁽⁷⁸⁻⁷⁹⁾. Consistently, hepatocytic mutation of *Bmal1* impairs the entire autophagic process in murine liver. The CC also modulates the ER stress-induced activation of the UPR-driven gene expression program ^(78,80). Physiologically, the UPR is necessary to restore cellular secretory capacity following an accumulation of misfolded proteins in the ER and functions by degrading unfolded proteins and activating the expression of chaperones which enable protein folding ⁽⁸¹⁾. The CC by generating ultradian (lesser than a day) rhythms in the expression of UPR master regulators i.e. the inositol-requiring enzyme1 α (IRE1 α) and the X-box binding protein1 (XBP1) controls the expression of several genes within the UPR pathway ^(78,80). Moreover, by regulating activation of the transcription factor CREBH ⁽⁸²⁾ and expression of the deadenylase CPEB4 ⁽⁸³⁾, the CC extends control over the ER-stress response pathway. Deregulation in reactive oxygen species (ROS)

production and scavenging have been implicated in the development of NAFLD and NASH. To avoid the dangers of excessive ROS levels, cells are dependent on anti-oxidant enzymes. Interestingly, expressions and activities of several enzymes, e.g. glutathione reductase, superoxide dismutase, glutathione peroxidase and peroxiredoxins display CC-controlled diurnal rhythms⁽⁸⁴⁻⁸⁵⁾. Consistently, in peripheral tissues levels of ROS as well as peroxidized lipids/proteins vary per the light-dark cycle⁽⁸⁶⁾. Thus, it is evident that the 'clock' plays a remarkable role in regulating several cellular processes where deregulation have been strongly implicated in chronic liver diseases (Figure 3).

Circadian clock, nuclear receptors (NRs) and NAFLD

The nuclear receptor (NR) superfamily which comprises 48 members in humans, control diverse aspects of physiology including metabolism⁽⁸⁷⁻⁸⁹⁾. NRs are transcription factors, which upon ligand (natural and synthetic) binding drive gene expression programs, amongst whom are pathways controlling metabolism. Investigation of the circadian expression patterns of all NRs in four mice tissues, including, the liver⁽⁶⁰⁾, revealed that at least 20 of the 41 transcribed NR in the murine liver are expressed in a circadian manner thereby providing a possible molecular link between the clock, NRs, and metabolism. In the liver, NRs control a broad range of crucial hepatic functions and are prominently implicated in NAFLD development^(38,88-89). Here, we briefly discuss a few of these NRs that are not only known to be regulated by the 'clock' but also have emerged as therapeutic targets for NAFLD (see below). PPAR α regulates β -oxidation and ketogenesis⁽⁹⁰⁾ and plays a prominent role in inflammation by trans-repressing NF- κ B and AP-1 pathways⁽⁹¹⁾. Importantly, genetic studies in mice indicate that through this trans-repressive activity PPAR α can prevent fibrosis development which is a crucial event in NASH pathogenesis⁽⁹¹⁾. Ligand activation of PPAR β/δ (which plays a prominent role in lipid catabolism) also prevents hepatic fibrogenesis⁽⁹²⁾. The Liver X receptors (LXRs) are transcriptional regulators of cholesterol metabolism and hepatic lipogenesis, and LXR activation lowers atherosclerosis by enhancing reverse cholesterol transport⁽⁸⁹⁾. Whereas LXR could be a possible antifibrotic target⁽⁹³⁾, LXR- activation enhances lipogenesis due to LXR-induced activation of SREBP1c activity⁽⁹³⁾. Lastly, with the establishment of pleiotropic roles of BAs in metabolic regulation, FXR has gained considerable attention as a therapeutic target for NAFLD (see below). Indeed, hepatic FXR activation reduces lipogenesis and improves fibrosis⁽⁷²⁾.

Clock, gut microbiota and NAFLD

Besides liver-restricted functions and processes, extrahepatic tissues also play a crucial role in NAFLD. Obesity-associated alterations in the gut microbiota (i.e., dysbiosis) composition and their interactions with the host (intestinal epithelial cells; IEC) have been implicated as an etiological agent in the pathogenesis of metabolic diseases, including NAFLD⁽⁹⁴⁻⁹⁷⁾. A mechanism through which changes in gut microbiota composition may promote NAFLD is through increased LPS production and delivery to the liver via the portal circulation⁽⁹⁸⁻⁹⁹⁾. In turn, microbiota-derived LPS can perturb hepatic lipid metabolism by modulating the production of short-chain fatty acids and altering the BA pool composition⁽⁹⁹⁾, which may influence intestinal and hepatic FXR activity, thus affecting both glucose and lipid homeostasis⁽⁹⁹⁾. Remarkably, the CC by regulating the expression of microbial pattern recognition receptors (e.g. TLRs, NOD2) provides a ‘temporal window’ during which microbiota-signals regulate gene expression to maintain homeostasis⁽¹⁰⁰⁾. Interestingly, the gut microbiota also displays ‘clock’-controlled diurnal rhythmicity⁽¹⁰¹⁻¹⁰²⁾. Consistently, circadian perturbations (mutation of CC-components or jet lag) lead to dysbiosis and development of metabolic pathologies⁽¹⁰¹⁾. Furthermore, mutation of innate immune genes (*Tlr5*, *Nlrp6*, *Nlrp3*) which play pivotal roles in sensing gut microbiota, modulate metabolic pathologies, including NAFL⁽⁹⁵⁾.

Chronopharmacology: detoxification, pharmacokinetics, and dynamics

Considering its overall influence on physiology, it is hardly surprising that clinically relevant pharmacological aspects, e.g. pharmacokinetics (PK) and pharmacodynamics (PD), of many drugs are also governed by the ‘clock’, thereby introducing circadian variations in drug metabolism/detoxification and efficacy^(84,103). One of the most prominent examples of circadian control over pharmacology emerges from its ability to regulate almost every step of xenobiotic detoxification in the liver, including absorption, biotransformation and elimination^(84,103-104). Notably, in humans, hepatic absorption of lipophilic drugs occurs more swiftly in the morning than in the evening⁽¹⁰³⁾. Consistently, expression of several transport proteins which mediate xenobiotic uptake e.g. cationic and anionic transporters (*Oct-1*, *Oatp1*, *Oatp1a4* etc.) display circadian rhythmicity⁽¹⁰³⁾. Classically, xenobiotic metabolism is grouped into three (I, II, and III) phases. Phase I involves biochemical modification of substrates by the CYP450 superfamily of enzymes. Importantly, transcript levels of several members (*Cyp2a4*, *Cyp2a5*, *Cyp2b10*, *Cyp2e1*, *Cyp3a11* etc.) of this family are rhythmic, attaining in mouse liver their peak during the rest phase^(84,104). In phase II, xenobiotics are rendered hydrophilic by conjugation to various small molecules.

Notably, phase II controlling genes (*Sult1c1*, *Sult1d1*, *Gsta1*, *Gsta2* etc.) are also expressed in a circadian manner. The excretion of xenobiotics (phase III) is controlled by different transporter proteins, and several of them (*Mrp2*, *Mdr2*, *Abcg2*, *Abcc2* etc.) oscillate rhythmically in the mouse liver. This pervasive circadian control of all these phases is molecularly achieved by hepatic CC-driven regulation of TFs, enzymes and transport proteins participating in the detoxification process^(84,104). Hepatic expression of TFs (PXR, CAR and AhR), which bind and metabolize xenobiotics, is rhythmic⁽⁶⁰⁾. Moreover, CC-components (ROR α/γ) and CC-output regulators (DBP, HLF and TEF) also transcriptionally regulate the detoxification process⁽¹⁰⁵⁻¹⁰⁶⁾. Accordingly, mice with ablation of the *Dbp*, *Hlf* and *Tef* genes exhibit widespread deficiencies in both basal and inducible detoxification processes⁽¹⁰⁶⁾.

Circadian control of ‘pharmacology’ extends beyond the liver and has been reviewed elsewhere^(84,107). ‘Timing’ is of crucial but less-appreciated factor in drug efficacy. Indeed, 56 of the top 100 best-selling drugs in the USA target the product of a circadian gene⁽¹⁰⁸⁾. However, most of them are yet to be associated and dosed as per the circadian rhythm. Importantly, clock perturbations resulting from HFD feeding can be rescued by ‘properly-timed’ pharmacological interventions⁽¹⁰⁹⁾. Taken together, recent studies (although many in rodent models) suggest that it will be highly prudent to investigate the mechanistic basis of circadian variations in PK/PD, in order to include a ‘circadian’ component for better therapeutic outcomes^(84,107).

Therapeutic impact: CC and pharmacological targeting of NAFLD

While licensed pharmacological therapies are not yet available⁽³⁶⁻³⁸⁾, a larger number of approaches and compounds are in preclinical and clinical development. Most therapeutic strategies aim to decrease inflammation, fibrosis, and metabolic substrate availability or to increase their disposal from the liver. Weight loss management or bariatric surgery not only improves NASH, but can also induce fibrosis regression^(38, 110). Considering the key impact of CC-control in regulation of metabolism, it is likely that the molecular targets of several drug candidates are CC-regulated. For example, obeticholic acid (INT-747) which activates FXR, reverses histological features of NASH⁽¹¹¹⁾ and the CC is well known to control BA metabolism. Interestingly, FGF19 which is rhythmically secreted from intestine (post-feeding) has efficacy in murine models of NASH⁽¹¹²⁾. Importantly, treatment with the FGF19 analog NGM282 reduces hepatic fat content in NASH patients⁽¹¹³⁾. The CC-regulated NRs PPAR- α/β are activated by elafibranor (currently in phase 3 trial), which enhances lipid metabolism, insulin sensitivity and reduces inflammation⁽¹¹⁴⁾. Furthermore, FGF21, a direct transcriptional target of PPAR α reduces

steatosis ⁽³⁷⁾. Significantly, some other potential NASH-modulating compounds ⁽³⁷⁻³⁸⁾, e.g. resveratrol (SIRT1-agonist), inhibitors of acetyl-CoA carboxylase (ACC) and FAS, further strengthen the CC-connection to therapeutics.

The intimate relationship between metabolism and the CC, as well as the amenability of the CC-oscillator to a variety of 'resetting' signals ⁽¹⁻⁷⁾, has spurred investigations to explore the potential of 'clock' modulating small molecules as a possible treatment for metabolic disorders ⁽¹¹⁵⁻¹¹⁸⁾. Using high-throughput phenotypic screening or medicinal chemistry approaches several molecules affecting the affect circadian period, phase and/or amplitude have been identified ⁽¹¹⁵⁻¹¹⁸⁾. Consistent with the molecular-genetic studies revealing a regulatory role for PERs and CRYs in CC-functioning, several compounds have been found to affect their levels and alter (mostly lengthening) circadian periods ⁽¹¹⁵⁻¹¹⁷⁾. One such compound, KL001 was found to bind CRY proteins which prevented their ubiquitination and proteasomal degradation ^(116,119). Consistent with the known role of CRYs in suppressing gluconeogenesis, KL001 administration was shown to improve glucose tolerance in diet-induced obese (DIO) mice ^(116,120). Recent investigations have also identified several modulators of CC-components ROR α / γ and REV-ERB α / β with therapeutic potential in animal models of metabolic disorders ⁽¹¹⁶⁻¹¹⁸⁾. In this regard, agonists of REV-ERBs; e.g., SR9009 and SR9011 ⁽¹²¹⁾, and an inverse ROR agonist of (SR1555) ⁽¹²²⁾ were found to improve several metabolic parameters in DIO mice. Amongst identified ROR modulators nobiletin (NOB) was demonstrated to enhance the amplitude of the CC, reduce weight gain, improve energy homeostasis and metabolic parameters in both DIO and genetically diabetic (*db/db*) mice ^(116-118, 123). Taken together, these small molecule modulators of CC-components provide an opportunity to further reveal regulatory networks in circadian functioning which could be targeted, alone or in combination, to treat metabolic liver disease.

CC and alcohol-induced liver disease (ALD)

Like NAFLD, pathogenesis of alcohol-induced liver disease (ALD) is complex and arises from interactions between metabolic, environmental and genetic risk factors in heavy alcohol consumers. In the context of alcohol-related disease, the CC has largely been investigated from a neurobehavioral perspective, noting CC disruption in alcohol use disorders and addiction ⁽¹²⁴⁻¹²⁵⁾. For example, rotating shift-workers have increased alcohol intake and tendencies to engage in binge drinking ⁽¹²⁶⁾. Genetic variants in some clock genes are also associated with alcohol dependence and increased drinking in humans ⁽¹²⁷⁻¹²⁸⁾. Finally, transcript levels of CC genes are significantly lower in peripheral blood mononuclear cells from alcohol-dependent patients

compared with healthy control subjects ⁽¹²⁹⁾. Together, these studies suggest that CC alterations could promote alcoholic disorders and excessive alcohol consumption.

Investigations using *Per2::Luciferase* knock-in mice demonstrated that alcohol consumption misaligns peripheral clocks from the master SCN clock ⁽¹³⁰⁻¹³¹⁾. Additionally, in liver, chronic alcohol consumption disrupts rhythmic oscillations of several CC components and CC-controlled output genes involved in regulating glucose, glycogen, cholesterol, BA and FFA metabolism ^(130, 132). For example, chronic alcohol intake in mice alters the diurnal rhythm in hepatic glycogen content due to dampened and/or shifted oscillations in glucose and glycogen metabolism genes ^(57, 132). Moreover, liver-specific BMAL1 deletion and chronic alcohol abolish day-night differences in hepatic glycogen content ⁽¹³²⁾. Alcohol consumption also disrupts rhythmic oscillations in the cofactor NAD⁺ ⁽¹³⁰⁾ required for numerous metabolic functions in the liver, including pathways regulated by SIRT1 and PARP-1. Furthermore, CC disruption (mutation or disrupting the light-dark cycle) enhances alcohol-induced tissue injury in mice. For example, alcohol-induced steatosis is higher in livers of *Clock*-mutant mice as compared to wild-type mice ⁽¹³³⁾. Liver-specific deletion of BMAL1 also increases hepatic steatosis in mice treated with chronic plus binge alcohol ⁽¹³⁴⁾. Moreover, CC-disruption through weekly 12-h shifts in the light-dark cycle, increases gut leakiness and liver injury in alcohol-fed mice ⁽¹³⁵⁾. Importantly, whole gut and colon permeability is enhanced in night-shift but not in day-shift workers who consumed moderate amounts of alcohol (0.5 g/kg/day) for only one week ⁽¹³⁶⁾. Collectively, these studies suggest that CC disruption may increase risk for liver disease in alcohol consumers. Importantly, as key mechanisms and linkages among alcohol-mediated CC disruption, metabolic dysregulation, and tissue injury emerge, it may become possible to pharmacologically target the CC in ALD patients.

Conclusion and future perspectives

The pathogenesis of NAFL and its progression to NASH, the most-prevalent noninfectious liver disease, is complex and multifactorial. Both genetic factors as well as the environment have been shown to play important functional roles. Perturbations in FFA metabolism, which lies at the core of NAFLD could potentially arise from deregulation of several distinct mechanisms. Remarkably, under physiological conditions most of these processes are governed by the CC-machinery. Consistently, in mice models, either mutation of CC-components ⁽¹⁻⁵⁾ or change in the feeding time ⁽¹³⁷⁾ are closely associated with a range of metabolic diseases including NAFL. Importantly, recent investigations have categorically established that in humans 'circadian misalignment' has adverse metabolic and cardiovascular consequences ⁽¹³⁸⁻¹³⁹⁾. Furthermore, epidemiologically, single

nucleotide polymorphisms (SNPs) in the *Clock* gene ⁽¹⁴⁰⁾ and in several CC-controlled transcriptional regulators (e.g. *Ppar γ* , *Stat3*, *Ppargc1 α*) ⁽⁸⁸⁾ and the enzyme *Pnpla3* ⁽¹⁴¹⁾ are associated with the development of obesity, metabolic syndrome, NAFLD and NASH. Most significantly, our *nouveau* life-style (nutrient-dense foods, timing of eating and activity) which continuously interferes with endogenous circadian rhythms is also epidemiologically correlated with increasing incidences of all the hallmarks of metabolic syndrome including, NAFLD ⁽⁸⁻¹²⁾. Given the socio-economic realities in modern societies, it is difficult to avoid circadian disruption. Thus, in addition to life-style modification, CC-targeting approaches may provide therapeutic opportunities overcoming these challenges. Furthermore, comprehensive systems level investigations of the circadian system elucidating physical- and genetic-interaction networks will reveal novel targets to prevent and treat chronic liver disease.

Acknowledgements

The authors apologize to colleagues whose work could not be cited due to space limitations.

Funding

This work was supported by the ERC-AdG-2014-671231-HEPCIR, EU H2020-667273-HEPCAR, the National Institute of Health (NIAID 1R03AI131066-01A1, NCI R21 CA209940), the Fondation ARC pour la Recherche sur le Cancer (TheraHCC IHUARC IHU201301187). The work has been published under the framework of LABEX ANR-10-LABX-0028-HEPSYS, ANR-10-LABEX-0046, Inserm Plan Cancer and, benefits from the state managed funding by the French National Research Agency as part of the investments for the future program. BS and TFB hold advanced ERC grants (694717, 671231).

References

1. Asher G, Schibler U. Crosstalk between components of circadian and metabolic cycles in mammals. *Cell Metab* 2011; 13: 125-137.
2. Eckel-Mahan KL, Sassone-Corsi P. Metabolism and the circadian clock converge. *Physiol Rev* 2013; 93:107-135.
3. Bass J. Circadian topology of metabolism. *Nature* 2012; 491: 348-356.
4. Feng D, Lazar MA. Clocks, Metabolism and Epigenome. *Mol Cell* 2012; 47:158-167.
5. Asher G, Sassone-Corsi P. Time for food: The intimate interplay between nutrition, metabolism and the circadian clock. *Cell* 2015; 161: 84-92
6. Panda S. Circadian physiology of metabolism. *Science* 2016; 354: 1008-1015.

7. LeGates TA, Fernandez DC, Hattar S. Light as a central modulator of circadian rhythms, sleep and affect. *Nat Rev Neurosci* 2014; 15: 443-454.
8. Takahashi JS, Hong HK, KO CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. *Nat Rev Genet* 2008; 9:764-775.
9. Wang X-S, Armstrong MEG, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. *Occup Med* 2011; 61: 78–89.
10. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. *J Clin Invest*; 2011;121: 2133-2141.
11. Colles SL, Dixon JB, O’Brien PE. Night eating syndrome and nocturnal snacking: association with obesity, binge eating and psychological distress. *Int J Obes* 2007; 31: 1722–1730.
12. Sun M, Feng W, Wang F, Zhang L, Wu Z et al. Night shift work exposure profile and obesity: Baseline results from a Chinese night shift worker cohort. *Plos One* 2018; 13: e0196989.
13. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. *Epidemiology* 2005; 16:254-258.
14. Takahashi JS. Transcriptional architecture of the mammalian circadian clock. *Nat Rev Genet* 2017; 18:164-179.
15. **Damiola F, LeMinh N**, Preitner N, Kornmann B, Fleury-Olela F et al. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes Dev* 2000; 14: 2950–2961.
16. **Stokkan KA, Yamazaki S**, Tei H, Sakaki Y, Menaker, M. Entrainment of the circadian clock in the liver by feeding. *Science* 2001; 291: 490–493.
17. Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. *Proc Natl Acad Sci USA* 2009; 106: 21453–21458.
18. **Mukherji A, Kobiita A**, Chambon P. Shifting the feeding of mice to the rest phase creates metabolic alterations, which, on their own, shift the peripheral circadian clocks by 12 hours. *Proc Natl Acad Sci USA* 2015; 112: E6683-E6690.
19. Eckel-Mahan KL, Patel VR, deMateo S, Orozco-Solis R, Ceglia NJ. Reprogramming of the circadian clock by nutritional challenge. *Cell* 2013; 155: 1464–1478.
20. **Hatori M, Vollmers C, Zarrinpar A**, DiTacchio L, Bushong EA. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. *Cell Metab* 2012; 15: 848–860.
21. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD⁺ salvage pathway by CLOCK-SIRT1. *Science* 2009; 324: 654–657.
22. **Ramsey KM, Yoshino J, Brace CS**, Abrassart D, Kobayashi Y. Circadian clock feedback cycle through NAMPT-mediated NAD⁺ biosynthesis. *Science* 2009; 324: 651–654.
23. Kaasik K, Lee C. Reciprocal regulation of heme biosynthesis and the circadian clock in mammals. *Nature* 2004; 430: 467–471.
24. Yin L, Wu N, Curtin JC, Qatanani M, Szwegold NR, et al. Rev-erb α , a heme sensor that coordinates metabolic and circadian pathways. *Science* 2007; 318: 1786–1789.
25. Koike N, Yoo S-H, Huang H-C, Kumar V, Lee C et al. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. *Science* 2012; 338: 349–354.
26. Rey G, Cesbron F, Rougemont J, Reinke H, Brunner M et al. Genome-wide and phase-specific DNA-binding rhythms of BMAL1 control circadian output functions in mouse liver. *PLoS Biol* 2011; 9: e1000595.
27. Cho H, Zhao X, Hatori M, Yu RT, Barish GD et al. Regulation of circadian behaviour and metabolism by REV-ERB- α and REV-ERB- β . *Nature* 2012; 485: 123-127.

28. **Fang B, Everett LJ, Jager J**, Briggs E, Armour SM et al. Circadian enhancers coordinate multiple phases of rhythmic gene transcription in vivo. *Cell* 2014; 159:1140-1152.
29. **Panda S, Antoch MP**, Miller BH, Su AI, Schook AB et al. Coordinated transcription of key pathways in the mouse by the circadian clock. *Cell* 2002; 109: 307–320.
30. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC et al. Extensive and divergent circadian gene expression in liver and heart. *Nature* 2002; 417:78-83.
31. Robles MS, Cox J, Mann M (2014). In-vivo quantitative proteomics reveals a key contribution of post-transcriptional mechanisms to the circadian regulation of liver metabolism. *PLoS Genet* 2014 ; 10 : e1004047.
32. **Mauvoisin D, Wang J**, Jouffe C, Martin E, Atger F et al. Circadian clock-dependent- and - independent rhythmic proteomes implement distinct diurnal functions in mouse liver. *Proc Natl Acad Sci USA* 2014; 111: 167–172.
33. **Wang J, Mauvoisin D**, Martin E, Atger F, Galindo AN et al. Nuclear proteomics uncovers diurnal regulatory landscapes in mouse liver. *Cell Metab* 2017; 25: 102–117.
34. Aviram R, Manella G, Kopelman N, Neufeld-Cohen A, Zwihaft Z et al. Lipidomic analyses reveal temporal and spatial lipid organization and uncover daily oscillations in intracellular organelles. *Mol Cell* 2016; 62:636-648.
35. Adamovich Y, Rousso-Noori L, Zwihaft Z, Neufeld-Cohen A, Golik M et al. Circadian clocks and feeding time regulate the oscillations and levels of hepatic triglycerides. *Cell Metab* 2014; 19: 319–330.
36. Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. *Cell Metab* 2018; 27:22-41.
37. Friedmann SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med* 2018; 24: 908-922.
38. Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. *Annu. Rev. Physiol.* 2016; 78:181-205.
39. Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. *Curr Opin Virol* 2015; 14:41-46.
40. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. *Gut* 2015; 64:1314-1326.
41. Chung RT, Baumert TF. Curing chronic hepatitis C- the arc of a medical triumph. *N Engl J Med* 2014; 370: 1576-1578.
42. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. *J Hepatol* 2014; 61: S79-S90.
43. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis-perspectives and challenges. *J Hepatol* 2013; 58:375-384.
44. Younossi ZM, Blissett D, Blissett R, Henry L et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. *Hepatology* 2016; 64: 1577–1586.
45. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. *J Clin Invest* 2016; 126: 12-22.
46. Heyman F, Tacke F. Immunology in the liver-from homeostasis to disease. *Nat Rev Gastroenterol Hepatol* 2016; 13:88-110.
47. Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. *Hepatology* 2015; 61:1066-1079.
48. Ganz M, Szabo G. Immune and inflammatory pathways in NASH. *Hepatol Int.* 2013; 7:771-781.
49. Day CP, James OF. Steatohepatitis: a tale of 'two' hits? *Gastroenterology* 1998; 114:842-845.

50. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. *Hepatology* 2010; 52:774-88.
51. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Investig.* 2005; 115:1343-1351.
52. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology* 2014; 146:726-735.
53. Hirsova P, Ibrahim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. *J Lipid Res* 2016; 57:1758-1770.
54. Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. *Metabolism* 2016; 65:1049-1061.
55. Kalsbeek A, LaFleur S, Fliers E. Circadian control of glucose metabolism. *Mol Metab* 2014; 3: 372-383.
56. Lamia KA, Storch KF, Weitz CJ. Physiological significance of a peripheral tissue circadian clock. *Proc Natl Acad Sci U S A* 2008;105: 15172–15177.
57. Udoh US, Swain TM, Filiano AN, Gamble KL, Young ME. Chronic ethanol consumption disrupts diurnal rhythms of hepatic glycogen metabolism in mice. *Am J Physiol Gastrointest Liver Physiol* 2015; 308: G964-974.
58. Kaasik K, Kivimae S, Allen JJ, Chalkley RJ, Huang Y et al. Glucose sensor O-GlcNAcylation coordinates with phosphorylation to regulate circadian clock *Cell Metab.* 2013; 17: 291–302.
59. Guillaumond F, Grechez-Cassiau A, Subramaniam M, Brangolo S et al. Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver. *Mol Cell Biol* 2010; 30:3059–3070.
60. Yang X, Downes M, Yu RT, Bookout AL, He W et al. Nuclear receptor expression links the circadian clock to metabolism. *Cell* 2006; 126: 801–810.
61. **Zhang EE, Liu Y**, Dentin R, et al. Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. *Nat Med* 2010; 16:1152–1156.
62. Liu C, Li S, Liu T, Borigin J, Lin JD. Transcriptional coactivator PGC1- α integrates mammalian clock and energy metabolism. *Nature* 2007; 447:477-481.
63. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G et al. Obesity and metabolic syndrome in circadian Clock mutant mice. *Science* 2005; 308:1043–1045.
64. Grimaldi B, Bellet MM, Katada S, Astarita G, Hirayama J et al. PER2 controls lipid metabolism by direct regulation of PPAR γ . *Cell Metab* 2010; 12: 509–520.
65. Paschos GK, Ibrahim S, Song W-L, Kuneida T, Grant G et al. Obesity in mice with adipocyte-specific deletion of clock component Arntl. *Nat Med* 2012; 18:1768-1777.
66. Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE et al. Rev-Erb α and Rev-Erb β coordinately protect the circadian clock and normal metabolic function. *Genes Dev* 2012; 26: 657–667.
67. Jordan SD, Lamia KA. AMPK at the crossroads of circadian clocks and metabolism. *Mol Cell Endocrinol* 2013; 366:163-169.
68. Chavan R, Feillet C, Fonesca Costa S, Delorme JE, Okabe T et al. Liver-derived ketone bodies are necessary for food anticipation. *Nat Commun* 2016;7: 10580.
69. Lemberger T, Saladin R, Vazquez M, Assimopoulos F, Staels B et al. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. *J Biol Chem* 1996; 271:1764-1769.
70. Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B et al. REV-ERB α participates in circadian SREBP signaling and bile acid homeostasis. *PLoS Biol* 2009;7: e1000181.


71. Thomas C, Pelliccari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signaling for metabolic disease. *Nat Rev Drugdisc* 2008;7:678-693.
72. Chàvez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. *Gastroenterol* 2017; 152:1679-1694.
73. Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. *Liver Res* 2017;1: 3-9.
74. Stroeve JH, Brufau G, Stellard F, Gonzalez FJ, Staels B et al. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. *Lab Invest* 2010; 90:1457-1467.
75. Lavery DJ, Schibler U. Circadian transcription of the cholesterol 7 alpha hydroxylase gene may involve the liver-enriched bZIP protein DBP. *Genes Dev* 1993; 7:1871–1884.
76. Duez H, Veen JN, Duhem C, Pourcet B, Touvier T et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erb α . *Gastroenterol* 2008; 135: 689-698.
77. Duane WC, Levitt DG, Mueller SM, Behrens JC et al. Regulation of bile acid synthesis in man. Presence of a diurnal rhythm. *J Clin Invest* 1983; 72:1930–1936.
78. Chaix A, Zarrinpar A, Panda S. The circadian coordination of cell biology. *J Cell Biol* 2016; 215: 15-25.
79. Ma D, Li S, Molusky MM, Lin JD (2012). Circadian autophagy rhythm: a link between clock and metabolism? *Trends Endocrinol Metab* 2012; 23: 319–325.
80. Cretenet G, Le Clech M, Gachon F. Circadian clock-coordinated 12Hr period rhythmic activation of the IRE1 α pathway controls lipid metabolism in mouse liver. *Cell Metab* 2010; 11: 47–57.
81. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 2007; 8:519-529.
82. **Zheng Z, Kim H**, Qiu Y, Chen X, Mendez R et al. CREBH couples circadian clock with hepatic lipid metabolism. *Diabetes* 2016 ; 65 :3369-3383.
83. Maillou M, Martín J, Sebastián D, Hernández-Alvarez M, García-Rocha M et al. Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress. *Nat Cell Biol* 2017; 19: 94–105.
84. Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. *Annu Rev Pharmacol Toxicol* 2014; 54: 339-361.
85. **Jacobi D, Liu S**, Burkewitz K, Kory N, Knudsen NH et al. Hepatic Bmal1 regulates rhythmic mitochondrial dynamics and promotes metabolic fitness. *Cell Metab* 2015; 22:709-720.
86. Kanabrocki EL, Murray D, Hermida RC, Scott GS, Bremner WF et al. Circadian variation in oxidative stress markers in healthy and typeII diabetic men. *Chronobiol Int.* 2002; 19:423-439.
87. Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR and the big bang. *Cell* 2014;157 P255-P266.
88. Mazzocchi G, Vinciguerra M, Oben J, Tarquini R, De Cosmo S. Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. *Liver Int* 2014; 34: 1133–1152.
89. Trauner M, Halilbasic E. Nuclear receptors as new perspectives for management of liver diseases. *Gastroenterology* 2011; 140:1120-1125.e1-12.
90. Pawlak M, Lefevre P, Staels B. Molecular mechanism of PPAR α action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J. Hepatol* 2015; 62:720-733.
91. Pawlak M, Bauge E, Bourguet W, De Bosscher K, Lalloyer F et al. The transrepressive activity of peroxisomal proliferator-activated receptor α is necessary and sufficient to prevent liver fibrosis in mice. *Hepatology* 2014; 60:1593-1606.
92. Iwasako K, Haimerl M, Paik YH, Taura K, Kodama Y et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. *Proc. Natl. Acad. Sci* 2012; 109:E1369-E1376.

93. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Ther Adv Gastroenterol* 2011; 4:391-417.
94. Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. *Nature* 2016; 535:56-64.
95. Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. *Mol Metab* 2016; 5:782-794.
96. Ray K. NAFLD: leaky guts: intestinal permeability and NASH. *Nat Rev Gastroenterol Hepatol* 2015; 12:123.
97. Van Olden C, Groen AK, Nieuwdorp M. Role of intestinal microbiome in lipid and glucose metabolism in diabetes mellitus. *Clin Ther* 2015; 37:1172-1177.
98. Cani P D, Bibiloni R, Knauf C, Waget A, Neyrinck AM et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 2008; 57: 1470-1481.
99. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for dyslipidemia and cardiovascular disease. *J Lipid Res.* 2012; 53:1723-1737.
100. Mukherji A, Kobiita A, Ye T, Chambon P. Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs. *Cell* 2013; 153:812–827.
101. Thaiss CA, Zeevi D, Levy M, Zilberman-Shapira G, Suez J et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. *Cell* 2014; 159:514–529.
102. Leone V, Gibbons SM, Martinez K, Hutchison AL, Huang EY et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. *Cell Host Microbe* 2015; 17:681–689.
103. Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. *Expert Opin Drug Metab Toxicol* 2008; 4:175-192.
104. Claudel T, Cretenet G, Saumet N, Gachon F. Crosstalk between xenobiotics metabolism and circadian clock. *FEBS Lett* 2007; 581:3626-3633.
105. **Kang HS, Angers M**, Beak JY, Wu X, Gimble JM et al. Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. *Physiol Genom* 2007; 31: 281-294.
106. Gachon F, Olela FF, Schaad O, Descombes P et al. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. *Cell Metab* 2006; 4:25–36.
107. Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GA. The role of clock genes in pharmacology. *Annu Rev Pharmacol Toxicol* 2010; 50:187-214.
108. Zhang R, Lahens NF, Balance HI, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. *Proc. Natl. Acad. Sci.* 2014; 111:16219-16224.
109. Woller A, Duez H, Staels B, Lefranc M. A mathematical model of the liver circadian clock linking feeding and fasting cycles to clock function. *Cell Reports* 2016; 17:1087-1097.
110. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; 51:121-129.
111. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomized placebo-controlled trial. *Lancet* 2015; 385:956-965.
112. Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT et al. Modulation of the intestinal bile acid/FXR/FGF15 axis improves alcoholic liver disease in mice. *Hepatology* 2018; 67:2150-2166.

113. Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2018; 391:1174-1185.
114. Ratziu V, Harrison SA, Francque S, Bedossa P, Leheret P et al. Elafibranor, an agonist of the peroxisome proliferator activated receptor α and δ induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. *Gastroenterology* 2016; 150:1147-1159.e5.
115. Wallach T, Kramer A. Chemical chronobiology: toward drugs manipulating time. *FEBS Lett.* 2015; 589: 1530-1538.
116. Cheng Z, Yoo SH, Takahashi JS. Development and therapeutic potential of small-molecule modulators of circadian systems. *Annu Rev Pharmacol Toxicol* 2018; 58:231-252.
117. Cheng Z, Yoo SH, Takahashi JS. Small molecule modifiers of circadian clocks. *Cell Mol Life Sci* 2013; 70: 2985-2998.
118. Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. *Nat. Rev. drug. Discov.* 2014; 13:197-216.
119. Hirota T, Lee JW, St John PC, Sawa M, Iwaisako K et al. Identification of small molecule activators of cryptochrome. *Science* 2012; 337: 1094-1097.
120. Humphries PS, Bershot R, Kincaid J, Marbery E, McCluskie K et al. Carbazole-containing sulfonamides and sulfamides: discovery of cryptochrome modulators as antidiabetic agents. *Bioorg Med Chem Lett* 2016; 26: 757-760.
121. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ et al. Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. *Nature* 2012; 485: 62-68.
122. Chang MR, He Y, Khan TM, Kuruvilla DS, Garcia-Ordenez R et al. Antiobesity effect of a small molecule repressor of ROR γ . *Mol Pharmacol* 2015; 88:48-56.
123. He B, Nohara K, Park N, Park YS, Guillroy B et al. The small molecule nobiletin targets the molecular oscillator to enhance circadian rhythms and protect against metabolic syndrome. *Cell Metab* 2016; 23:610-621.
124. Prosser RA, Glass JD. Assessing ethanol's actions in the suprachiasmatic circadian clock using in vivo and in vitro approaches. *Alcohol.* 2015;49:321-339.
125. Rosenwasser AM. Chronobiology of ethanol: Animal models. *Alcohol.* 2015; 49:311-319.
126. Virtanen M, Jokela M, Nyberg ST, Madsen IE, Lallukka T et al. Long working hours and alcohol use: systematic review and meta-analysis of published studies and unpublished individual participant data. *BMJ.* 2015;350: g7772.
127. Blomeyer D, Buchmann AF, Lascorz J, Zimmermann US, Esser G et al. Association of per2 genotype and stressful life events with alcohol drinking in young adults. *PLoS One.*2013;8:e59136
128. Kovanen L, Saarikoski ST, Haukka J, Pirkola S, Aromaa A et al. Circadian clock gene polymorphisms in alcohol use disorders and alcohol consumption. *Alcohol* 2010;45:303-311
129. Huang MC, Ho CW, Chen CH, Liu SC, Chen CC et al. Reduced expression of circadian clock genes in male alcoholic patients. *Alcohol Clin Exp Res.* 2010;34: 1899-1904.
130. Filiano AN, Millender-Swain T, Johnson R Jr., Young ME, Gamble KL et al. Chronic ethanol consumption disrupts the core molecular clock and diurnal rhythms of metabolic genes in the liver without affecting the suprachiasmatic nucleus. *PLoS One.* 2013;8:e71684.
131. Zhou P, Ross RA, Pywell CM, Liangpunsakul S, Duffield GE. Disturbances in the murine hepatic circadian clock in alcohol-induced hepatic steatosis. *Scientific reports.* 2014; 4:3725.
132. Bailey SM. Emerging role of circadian clock disruption in alcohol-induced liver disease. *Am J Physiol Gastrointest Liver Physiol.* 2018;315:G364-G373
133. Kudo T, Tamagawa T, Shibata S. Effect of chronic ethanol exposure on the liver of clock-mutant mice. *J Circadian Rhythms.* 2009; 7:4


134. Zhang D, Tong X, Nelson BB, Jin E, Sit J et al. The hepatic bmal1/akt/lipogenesis axis protects against alcoholic liver disease via promoting ppar alpha pathway. *Hepatology*. 2018; 68:883-896.
135. Summa KC, Voigt RM, Forsyth CB, Shaikh M, Cavanaugh K et al. Disruption of the circadian clock in mice increases intestinal permeability and promotes alcohol-induced hepatic pathology and inflammation. *PLoS One*. 2013;8 : e67102.
136. Swanson GR, Gorenz A, Shaikh M, Desai V, Kaminsky T et al. Night workers with circadian misalignment are susceptible to alcohol-induced intestinal hyperpermeability with social drinking. *Am J Physiol Gastrointest Liver Physiol*. 2016:ajpgi 00087 02016
137. Mukherji A, Kobiita A, Damara M, Misra N, Meziane H et al. Shifting eating to the circadian rest phase, misaligns the peripheral circadian clocks with the master SCN clock, which leads to a metabolic syndrome. *Proc Natl Acad Sci* 2015; 112: E6691-6698.
138. Scheer FAJL, Hilton MF, Mantozoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. *Proc. Natl.Acad Sci* 2009; 106:4453-4458.
139. Morris CJ, Purvis TE, Hu K, Scheer FAJL. Circadian misalignment increases cardiovascular disease risk factors in humans. *Proc. Natl. Acad Sci* 2016; E1402-E1411.
140. Sookian S, Castano G, Gemma C, Gianotti TF et al. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. *World J Gastroenterol* 2007; 13:4242-4248.
141. **Romeo S, Kozlitina J**, Xing C, Pertsemlidis A, Cox D et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; 40:1461-1465.

Figure 1. The molecular architecture of the Circadian Clock (CC)-oscillator




The recruitment of BMAL1/ CLOCK- heterodimer to the E-Box DBS present in the promoter-enhancer elements of numerous CCGs, including *Periods* (*Per1/2*) and *Cryptochromes* (*Cry1/2*) augment their expression during the rest phase. Following accumulation, PERs and CRYs proteins dimerize and translocate to inhibit BMAL1/CLOCK-dependent transcription during the active phase. Next, post-translational modifications including ubiquitination induce proteasomal degradation of PERs and CRYs, thus, initiating the next circadian cycle. In the second loop, BMAL1/CLOCK-dependent expression of *Rev-Erba*/ β during the rest phase, leads to the trans-repression of several RORE-DBS-containing CCGs including, *Bmal1*, *Clock* and *E4BP4*. In the active phase, the reduction in REV-ERBs levels permit the ROR α/γ -dependent RORE-mediated activation of CCGs including *Bmal1* and *Clock*, which enables the turning of the circadian clock. Furthermore, DBP expression during the rest phase activates D-Box DBS containing CCGs, which are transcriptionally repressed by E4BP4 during the active phase. These coupled transcriptional-translational regulatory circuits are ubiquitously present in almost all cell types and directly control the expression of a vast number of mammalian genes. CCG-Clock Controlled Genes. E-CCGs: E-Box DBS-containing CCGs, R-CCGs: RORE-containing CCGs, D-CCGs: D-Box-containing CCGs.

Figure 2. The clock controls the physiology of liver



Light-entrained central SCN-clock synchronizes peripheral tissue clocks including that of liver. The 'clock' machinery in turn drives the expression of several key transcription factors, rate limiting enzymes and transport proteins to spatiotemporally regulate several biochemical processes, which, together maintain physiological homeostasis. The 'clock'-connections to some of these processes and their connections to NAFLD and NASH have been discussed in detail.

Figure 3. Multidimensional connections of the 'clock' to the pathogenesis of fatty liver



Model representing a global view of how alterations in circadian clock-controlled 'rhythmic' functions/pathways and processes could predispose to non-alcoholic fatty liver disease. Knowledge of the mechanisms through which the 'clock'-system influences all these systems and essential pharmacological parameters, in turn, could be utilized to develop novel chronotherapeutics. Green arrowheads represent activation and red bar-heads represent inhibition. See text for details.